Immuneering (IMRX) Operating Expenses (2020 - 2023)
Historic Operating Expenses for Immuneering (IMRX) over the last 4 years, with Q4 2023 value amounting to $16.3 million.
- Immuneering's Operating Expenses rose 1656.38% to $16.3 million in Q4 2023 from the same period last year, while for Sep 2024 it was $16.3 million, marking a year-over-year decrease of 7093.93%. This contributed to the annual value of $58.4 million for FY2023, which is 1254.09% up from last year.
- Immuneering's Operating Expenses amounted to $16.3 million in Q4 2023, which was up 1656.38% from $13.9 million recorded in Q3 2023.
- Immuneering's Operating Expenses' 5-year high stood at $16.3 million during Q4 2023, with a 5-year trough of $3.9 million in Q2 2020.
- Its 4-year average for Operating Expenses is $10.7 million, with a median of $11.7 million in 2022.
- As far as peak fluctuations go, Immuneering's Operating Expenses surged by 11640.24% in 2021, and later soared by 544.51% in 2023.
- Immuneering's Operating Expenses (Quarter) stood at $6.0 million in 2020, then skyrocketed by 84.12% to $11.1 million in 2021, then rose by 26.01% to $14.0 million in 2022, then grew by 16.56% to $16.3 million in 2023.
- Its Operating Expenses was $16.3 million in Q4 2023, compared to $13.9 million in Q3 2023 and $13.5 million in Q2 2023.